Advanced Oncotherapy - Update on financing, suspension of trading on AIM
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy", "AVO" or the "Company")
Update on financing discussions and suspension of trading on AIM
Update re. publication of 2022 Annual Report & Accounts
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, provides the following update in relation to its current financing discussions, working capital position and its annual report and financial statements for its financial year ended
Update on financing discussions and suspension of trading on AIM
On
However, the Company was informed on
Whilst the Company has extended its cash runway and has been carefully managing its working capital, it is now in a highly constrained financial position and requires additional financing urgently in order to continue as a going concern. In the absence of any additional financing being available in the immediate term, the Company would need to take steps to preserve and maximise value for its creditors.
Whilst the Group continues to explore its options, the Board of Advanced Oncotherapy has requested that its shares be suspended from trading on AIM pending clarification of its financial position and trading in the Company's shares will be suspended at
Update re. publication of 2022 Annual Report & Accounts
As stipulated by Rule 19 of the AIM Rules for Companies the Company is required to publish its audited 2022 Annual Report by
|
Advanced Oncotherapy plc |
|
|
Dr. |
Tel: +44 (0) 20 3617 8728 |
|
|
|
|
|
|
|
WH Ireland Limited (Financial adviser) |
Tel: +44 (0) 20 7220 1666 |
|
|
|
|
|
|
|
Allenby Capital Limited (Nomad and Joint Broker) |
|
|
|
Tel: +44 (0) 20 3328 5656 |
|
|
|
|
SI Capital Ltd (Joint Broker) |
|
|
|
Tel: +44 (0) 1483 413 500 |
|
|
Tel: +44 (0) 20 3871 4066 |
|
|
|
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy, a
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE